z-logo
open-access-imgOpen Access
Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells
Author(s) -
Christoph Gstöttner,
Tao Zhang,
Anja Resemann,
Sophia Ruben,
Stuart Pengelley,
Detlev Suckau,
Tim Welsink,
Manfred Wuhrer,
Elena DomínguezVega
Publication year - 2021
Publication title -
analytical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.117
H-Index - 332
eISSN - 1520-6882
pISSN - 0003-2700
DOI - 10.1021/acs.analchem.1c00893
Subject(s) - chinese hamster ovary cell , chemistry , glycosylation , hek 293 cells , glycan , fucosylation , recombinant dna , computational biology , angiotensin converting enzyme 2 , receptor , biochemistry , covid-19 , glycoprotein , gene , biology , infectious disease (medical specialty) , medicine , disease , pathology
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is still ongoing and dramatically influences our life, the need for recombinant viral proteins for diagnostics, vaccine development, and research is very high. The spike (S) protein, and particularly its receptor-binding domain (RBD), mediates the interaction with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells and may be modulated by its structural features. Therefore, well-characterized recombinant RBDs are essential. We have performed an in-depth structural and functional characterization of RBDs expressed in Chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293) cells. To structurally characterize the native RBDs (comprising N - and O -glycans and additional post translational modifications), a multilevel mass spectrometric approach was employed. Released glycan and glycopeptide analysis were integrated with intact mass analysis, glycan-enzymatic dissection, and top-down sequencing for comprehensive annotation of RBD proteoforms. The data showed distinct glycosylation for CHO- and HEK293-RBD with the latter exhibiting antenna fucosylation, a higher level of sialylation, and a combination of core 1 and core 2 type O -glycans. Additionally, using an alternative approach based on N-terminal cleavage of the O-glycosylation, the previously unknown O-glycosylation site was localized at T323. For both RBDs, the binding to SARS-CoV-2 antibodies of positive patients and affinity to the ACE2 receptor was addressed showing comparable results. This work not only offers insights into RBD structural and functional features but also provides an analytical workflow for characterization of new RBDs and batch-to-batch comparison.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here